As the healthcare landscape continues to evolve, nursing careers are experiencing profound changes. Innovative technology, shifting patient demographics, and new healthcare models are all contributing to the transformation of this once-stalwart profession. Nurses today are tasked with providing direct patient care and increasingly taking on roles in leadership, research, and advocacy. As we look into the future, several key trends are expected to define nursing careers, influencing everything from job opportunities to the necessary skill sets. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
The Latest In Stem Cell Beauty Trends
Here are the powerful ways that stem cells are impacting the latest beauty trends.
In this article:
Cord Blood Banking Consolidates in All Major Markets in 2025
Cord blood and tissue banking is the collection and preservation of the valuable cells within the umbilical cord of a newborn for future medical use. For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of M&A activity in recent years. Today, more than 70% of the global cord blood market is controlled by the world’s ten largest cord blood banking operators. [Read more…]
BrightPath Bio and Cellistic Announce Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell
Tokyo, Japan and Mont-Saint-Guibert, Belgium – BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. [Read more…]
Stemcyte First Biotech to Receive FDA Approval of a Cord Blood Derived Cellular Therapeutic
FDA Grants Approval to StemCyte for REGENECYTE™ Cord Blood Cell Therapy
StemCyte Inc., a subsidiary of StemCyte International Ltd., has achieved a landmark in regenerative medicine with the U.S. Food and Drug Administration’s (FDA) approval of its Biologics License Application (BLA) for REGENECYTE™. Announced on November 22, 2024, this cord blood derived cellular therapeutic is designed to treat patients with blood and immune system disorders, making StemCyte the first commercial biotech company to receive a biologics license for a cord blood stem cell therapy. [Read more…]
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 62
- Next Page »